Navigation Links
ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Date:5/17/2010

LEUVEN, Belgium and LUND, Sweden, May 17, 2010 /PRNewswire-FirstCall/ --

- Trial to Study Patients with Colorectal and Ovarian Cancer

ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancers. ThromboGenics and co-development partner BioInvent will receive a milestone payment of EUR10 million from Roche under the terms of the strategic alliance agreement signed in June 2008. ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of all revenue from the alliance with Roche for this anti-cancer antibody.

This trial is a multi-centre, open-label (monotherapy), dose-finding study with intravenous TB-403. The primary objective of the study will be to establish the TB-403 concentration-pharmacodynamic (PD) effect relationship using DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) and to identify the minimally PD effective dose. The trial will recruit up to 50 patients across three European sites.

With the start of this study, Roche will assume responsibility for all future development of TB-403, continuing the work started by ThromboGenics and BioInvent. A Joint Steering Committee made up of representatives from Roche, ThromboGenics and BioInvent will continue to oversee research and development activities. In addition, Roche will continue to provide funding to ThromboGenics and BioInvent for re
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 30, 2015   Millar, Inc. , a leader ... the 2016 retirement of Craig Thummel , President/CEO ... years of service to the Company. The Company also ... members of the Executive Management team as his successors. ... , currently Director of Sales and Marketing, as President, ...
(Date:6/30/2015)... VALLEY, Pa. , June 30, 2015 /PRNewswire/ ... and delivering innovative solutions for medical and surgical ... is guaranteeing next-day replacements for surgical equipment at ... product manufacturer to offer this type of guarantee. ... Olympus Full Service Agreement earlier this year. ...
(Date:6/30/2015)... Calif. , June 30, 2015  Ardelyx, Inc. ... on cardio-renal, gastrointestinal and metabolic diseases, today announced that ... July 14, 2015, from 8:00 a.m.- 1:00 pm EDT ... The Ardelyx senior management team will present ... lead compound, tenapanor, which has completed Phase 2b clinical ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 2Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2
... The U.S. Food and Drug Administration is requiring ... on their labels about the risk of a ... systemic fibrosis (NSF), if the drug is administered ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo:   ...
... (Nasdaq: MSON ), a developer of ... which worldwide is used for acute health conditions, ... distribution agreement with Dismeval, s.l.,  based in Valencia, ... Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone ...
Cached Medicine Technology:FDA: New Warnings Required on Use of Gadolinium-Based Contrast Agents 2Misonix Announces New Distribution Agreement For Spain 2Misonix Announces New Distribution Agreement For Spain 3
(Date:6/30/2015)... ... June 30, 2015 , ... ... new video, “Grand Terrace Health Care Center.” Each year, Medicare ranks care centers ... find the best facility for their needs. Grand Terrace prides itself on quality ...
(Date:6/30/2015)... ... 2015 , ... According to a recent report by the U.S. Drug Enforcement ... than tripled in the same period—leading a majority of law enforcement agencies to cite ... leading Florida-based drug treatment facility, asserts that these heroin statistics point to an urgent ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... today that they have been awarded the exclusive billing agreements with Jackson Radiology ... of billing services encompassing their proprietary suite of billing process software functionality called ...
(Date:6/30/2015)... Angeles, CA (PRWEB) , ... June 30, 2015 , ... ... You Have Acne ,” listed five triggers that most people would not expect ... hair care products, and toothpaste. The primary causes of acne are clogged ...
(Date:6/30/2015)... ... 30, 2015 , ... Lakeview Health, a drug and alcohol ... of its medical staff to further enhance its ability to treat addiction patients ... and physician assistants -- now totals 17, compared to 7 in 2013, the ...
Breaking Medicine News(10 mins):Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2
... quality of patient care using Microsoft technology.CHICAGO, April ... and Microsoft Corp. today announced the winners of ... For more than a decade, the honors have ... systems integrators that have demonstrated significant advancements, innovation ...
... and renowned Smoking Cessation Specialist Franc Tausch achieves record success rates ... session , ... Los Angeles, CA (PRWEB) August 15, ... Angeles, California enables smokers to stop smoking for life ...
... or Hispanic, report finds , , MONDAY, April 6 (HealthDay News) ... well known, but researchers have now produced an overview of ... intermittent or occasional smokers, which the U.S. Centers for ... smokers in the country, is published in a series of ...
... that modifies the androgen receptor (AR) and influences its ability ... cancer. The research, published by Cell Press in the April ... also drive creation of new strategies for the treatment of ... therapies. , The AR is an important mediator for ...
... first four in nation to receive accreditationGREEN BAY, ... Medical Center is one of the first four ... the National Accreditation Program for Breast Centers (NAPBC), ... the first breast program in Wisconsin to earn ...
... expanding nationally OKLAHOMA CITY, April 6 ... franchise to combine practical and spiritual assistance, is opening ... Cordova, Tenn. is scheduled to open on April 8, ... services outside of Oklahoma," said Tony Vann, vice president ...
Cached Medicine News:Health News:Microsoft and Microsoft Health Users Group Announce Winners of Microsoft HUG 2009 Innovation Awards 2Health News:Microsoft and Microsoft Health Users Group Announce Winners of Microsoft HUG 2009 Innovation Awards 3Health News:Microsoft and Microsoft Health Users Group Announce Winners of Microsoft HUG 2009 Innovation Awards 4Health News:Hypnotherapy Breakthrough: Renowned Smoking Cessation Specialist Helps To Stop Smoking In One Session 2Health News:Researchers Profile the 'Light' Smoker 2Health News:A potential new target for treatment of hormone refractory prostate cancer 2Health News:Aurora BayCare is Wisconsin's First Nationally Accredited Breast Program 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: